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Abstract
Background: Fabry disease (FD) is an X-linked multisystemic disorder with a heterogeneous phenotype. Especially
atypical or late-onset type 2 phenotypes present a therapeutical dilemma.
Methods: To determine the clinical impact of the alpha-Galactosidase A (GLA) p.A143T/ c.427G > A variation, we
retrospectively analyzed 25 p.A143T patients in comparison to 58 FD patients with other missense mutations.
Results: p.A143T patients suffering from stroke/ transient ischemic attacks had slightly decreased residual GLA
activities, and/or increased lyso-Gb3 levels, suspecting FD. However, most male p.A143T patients presented with
significant residual GLA activity (~50 % of reference), which was associated with normal lyso-Gb3 levels. Additionally,
p.A143T patients showed less severe FD-typical symptoms and absent FD-typical renal and cardiac involvement in
comparison to FD patients with other missense mutations. Two tested female p.A143T patients with stroke/TIA did
not show skewed X chromosome inactivation. No accumulation of neurologic events in family members of p.A143T
patients with stroke/transient ischemic attacks was observed.
Conclusions: We conclude that GLA p.A143T seems to be most likely a neutral variant or a possible modifier instead
of a disease-causing mutation. Therefore, we suggest that p.A143T patients with stroke/transient ischemic attacks of
unknown etiology should be further evaluated, since the diagnosis of FD is not probable and subsequent ERT or
chaperone treatment should not be an unreflected option.
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Background
Fabry disease (FD; OMIM #301500) is an X-linked (Xq
22.1) inborn error of glycosphingolipid catabolism due to
deficient α-galactosidase A activity (GLA; 300644; [EC
3.2.1.22]). GLA mutations may lead to a classical or non-
classical FD phenotype [1]. A clear link between genotype
and phenotype in FD has not yet been established. Clas-
sical FD manifestations lead to clinical manifestations
such as early stroke, malignant cardiac arrhythmia, myo-
cardial infarction, cardiac failure, left ventricular hyper-
trophy (LVH) as well as progressive renal impairment,
associated with differential systemic cellular accumulation
of globotriaoslyceramide (Gb3). Several missense and non-
sense mutations are accompanied by nearly absent GLA
activities and increased lyso-Gb3 levels [2, 3]. Most non-
classical FD phenotypes result either from missense muta-
tions or from mutations within intronic or regulatory GLA
regions, lacking classical FD symptoms. Affected patients
suffer from late-onset organ manifestations such as cardio-
myopathy, kidney failure, stroke, or neuropathic pain ac-
companied by high residual GLA activities and lyso-Gb3
values within the reference values, as recently shown for
several non-classical FD mutations [4–12]. Due to the high
frequencies of private mutations in FD patients, most
genotype-phenotype relationships of controversially dis-
cussed mutations have been based on single case studies,
necessitating multicenter approaches with larger patient
groups carrying identical mutations. This approach will also
* Correspondence: Eva.Brand@ukmuenster.de
1Internal Medicine D, Department of Nephrology, Hypertension and
Rheumatology, University Hospital Muenster, Albert-Schweitzer-Campus 1,
D-48149 Muenster, Germany
Full list of author information is available at the end of the article
© 2016 Lenders et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Lenders et al. Orphanet Journal of Rare Diseases  (2016) 11:54 
DOI 10.1186/s13023-016-0441-z
allow for the assessment of whether affected patients may
benefit from enzyme replacement therapy (ERT).
Recent studies considered the c.427G > A (p.A143T)
GLA mutation to be more likely a neutral variant or a
possible modifier instead of a disease causing mutation
[10, 13]. In the current work, we retrospectively analyzed
the first visit of 25 ERT naïve adult female and male pa-
tients, carrying the controversially discussed p.A143T
variation in a multicenter study of four German FD cen-
ters and compared these data gender-specific to 58 ERT
naïve patients (39 females) with other missense GLA
mutations to determine a potential clinical impact of
p.A143T.
Methods
Study design and patients
Between July 2006 and March 2014 twenty-five genetically
confirmed adult heterozygous (females) and hemizygous
(males) FD patients with the p.A143T mutation were con-
secutively recruited at Fabry centers of the University hos-
pitals in Muenster, Wuerzburg, Cologne, and the Charité
Berlin. Patients were retrospectively analyzed in an open
cohort study and compared gender-specifically to 58 FD
patients with other missense mutations (n = 24). All pa-
tients including patients with p.A143T within this study
were either heterozygous (females) or hemizygous (males)
carriers for the corresponding GLA mutations. Missense
mutations included single nucleotide substitutions within
the GLA coding region, resulting in a single substitution of
amino acids, generally associated with a milder FD pheno-
type, compared to patients with nonsense mutations. A
detailed overview of all analyzed mutations is provided in
the supplement (Additional file 1: Table S1). All investiga-
tions were performed after approval of the Ethical Commit-
tees of the participating centers (Medical Association of
Westfalian-Lippe and the Ethical Committee of the Medical
Faculty of the University of Muenster; Ethical Committee
of the Medical Faculty of the University of Cologne; Ethical
Committee of the Medical Faculty of the University of
Wuerzburg; Ethical Committee of the Charite Berlin,
project-no: 2011–347-f; 14–328) and written informed con-
sent of the patients for molecular analysis and publication
was obtained.
A comprehensive diagnostic work-up had been per-
formed in all centers, including medical history and car-
diac, renal, and neurologic evaluation. The documentation
of assessments follows the clinical practice of the German
Fabry Expert Centers for a rare multisystemic disorder
[14]. Cardiac assessment included echocardiography and
electrocardiography. LVH was defined as an interventricu-
lar septum thickness in diastole (IVSd) >12 mm. Renal
function was quantified by the estimated glomerular filtra-
tion rate (eGFR) using the Chronic Kidney Disease-
Epidemiology Collaboration equation (CKD-EPI [15]) and
the albumin-to-creatinine ratio (ACR) from spot urine.
Renal impairment was defined as eGFR <90 ml/min/
1.73 m2 according to KDIGO guidelines [16] and albumin-
uria as ACR >30 mg albumin per g creatinine. All patients
underwent neurologic examination and a clinical interview
focusing on a history of stroke or transient ischemic attack
(TIA), and neuropathic pain. Strokes/TIAs were classified
according to Trial of ORG 10172 in Acute Stroke Treat-
ment (TOAST) criteria [17]. Disease severity scores were
assessed using the Mainz Severity Score Index (MSSI [18])
and the total Disease Severity Scoring System (DS3 [19]).
GLA sequencing, measurement of GLA activity and
plasma lyso-Gb3
Genotyping for GLA gene mutations was performed
by direct sequencing of all 7 coding exons including
adjacent intron-exons boundaries as previously re-
ported [20]. GLA activity was determined using 4-
methylumbelliferyl-α-D-galactopyranoside (Santa Cruz
Biotechnology, Heidelberg, Germany) as previously
described [21]. N-acetylgalactosamine (Santa Cruz
Biotechnology) was used as specific inhibitor of en-
dogenous α-Galactosidase B activity [22]. GLA en-
zyme activity was determined as nanomoles (nmol) of
substrate hydrolyzed per hour (h) per mg protein. For
plasma lyso-Gb3, lysoCeramide was used as reference
(Matreya LLC, Pleasant Gap, USA) and D5Fluticasone
Propionate (EJY Tech, Inc., Rockville, USA) served as
internal standard as described elsewhere. Plasma lyso-
Gb3 levels were measured in the lab of Arndt Rolfs
(University of Rostock, Germany). Reference values
for lyso-Gb3 were <0.9 ng/ml in plasma and for GLA
activity >32 nmol/h/mg protein in leukocytes. ERT-naïve
lyso-Gb3 values were available for 10 male and 14 female
p.A143T patients and 14 male and 26 female patients with
missense mutations. X chromosome inactivation analysis
was performed with genomic DNA from leukocytes using
a modified human androgen receptor (HUMARA) assay.
In short, 150 ng DNA were either incubated for 12 h at
37 °C with 4 units RsaI, or RsaI with HpaII (all New
England Biolabs, Frankfurt am Main, Germany). Thirty ng
DNA were used as template for subsequent amplification
with KAPAHifi (Peqlab, Erlangen, Germany) using the
primer combination HUM_fw: 5’-GCGCGAAGTGATCC
AG-3’ and HUM_rev: 5’GCCTCTACGATGGGCTTG-3’.
Amplicons were separated on a 3.5 % agarosegel and
stained with ethidium bromide. Subsequent analysis ac-
cording to Allen and colleagues [23] was performed with
ImageJ (NIH, Bethesda, USA; http://imagej.nih.gov/ij/).
Statistical analysis
Eighty-three patients from the participating FD centers
were included in the analysis. If not stated otherwise, con-
tinuous variables were expressed as mean with standard
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deviation, or in case of unequal distribution as median
[range]. Categorical data were expressed as numbers and
relative frequencies in percent. Differences between
groups were analyzed with the unpaired Student’s t or
Mann–Whitney U test for continuous data, and the Fish-
er’s exact test for categorical data. Statistical significance
was considered at a 2-sided p < 0.05.
All results are reported with their respective 95 % con-
fidence intervals (CI). SAS version 9.3 (SAS Institute
Inc, Cary, USA) and GraphPad PRISM V5.0 software
(GraphPad Software Inc., La Jolla, USA) were used for
all statistical analyses.
Results
An index patient for the current study was a female,
30 years of age, presenting at the IFAZ Muenster in
2012 after a stroke (media infarction) of unknown
etiology (Fig. 1a). The patient revealed an unrevealing
cardiovascular risk profile and no evidence of extracer-
ebral arteriopathy, vasculitis or other inflammatory
disease. Direct GLA sequencing identified the p.A143T
(c.427G > A, SNP# rs10489845) mutation, but plasma
lyso-Gb3 level was normal. A family screening identified
her father (age: 64 years), her uncle (father’s brother;
age: 63 years) with his daughter (age: 32 years) also with
the p.A143T variant. Although both males showed a
slightly reduced GLA activity of ~50 % of the reference
level none of the three relatives presented with increased
plasma lyso-Gb3 levels, nor other FD-typical organ man-
ifestations. The family history revealed strokes of her
paternal grandparents at a higher age, but not in any fur-
ther relatives of the index patient (neither in p.A143T
affected, nor unaffected). Since at this time-point no
other stroke-causing diseases could be detected within
the index patient, FD was diagnosed and ERT with
agalsidase-alfa was initiated, although the patient showed
no further FD-typical renal or cardiac manifestations.
Since the effect of the GLA p.A143T variation is dis-
cussed controversially and it has been recently described as
a non-pathogenic GLA variant instead of a FD-causing mu-
tation [10, 13], we retrospectively analyzed each first visit
between July 2006 and March 2014 of p.A143T patients, to
determine its potential clinical impact. Twenty-one add-
itional patients of another 11 unrelated families with the
p.A143T mutation were consecutively recruited at Fabry
centers in Muenster, Wuerzburg, Cologne and Berlin. A
summary of clinical symptoms and manifestations in pa-
tients with p.A143T and other missense mutations is pro-
vided in Table 1. Even if females with p.A143T suffered
more often from unspecific GI symptoms such as abdom-
inal pain (p = 0.0133) and diarrhea (p = 0.0048), all other
analyzed parameters did not differ (Table 1). For subse-
quent analyses, naïve p.A143T patients were gender-
specifically compared to naïve FD patients with other GLA
missense mutations concerning organ manifestations and
clinical events (Table 2). A detailed overview of the ana-
lyzed GLA mutations is provided in the supplement
(Additional file 1: Table S1). GLA activity in all tested hemi-
zygous males with p.A143T was below the reference, but
significantly higher compared to males with other missense
mutations (Table 2; Fig. 2a). GLA activity values in hetero-
zygous females with the p.A143T variant were lower
compared to heterozygous females with other missense
mutations (p < 0.05), but still above reference (Table 2;
Fig. 2a). In contrast to previous studies [13] no tissue biop-
sies have been performed.
Mean plasma lyso-Gb3 levels in p.A143T patients were
significantly lower than in patients with classical missense
mutations, so that most p.A143T patients showed normal
lyso-Gb3 values (lyso-Gb3 < 0.9 ng/ml: females: 85.7 %;
males: 77.8 %, Table 2). Linear regression analysis revealed
Fig. 1 Magnetic resonance (MR) images of p.A143T patients with cerebrovascular events. a Axial MRI of the index female patient (30 years of age)
suffering from an embolic stroke within the vascular territory of the right middle cerebral artery. b Coronal FLAIR-MRI of a male patient (38 years
of age) suffering from an embolic stroke within the vascular territory of the left middle cerebral artery. c FLAIR-MR of a female patient (46 years of
age) with TIAs and periventricular and subcortical microangiopathic and lacunar ischemic lesions (white arrow). FLAIR: fluid attenuated inversion
recovery. TIA: transient ischemic attack
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that male FD patients with missense mutations showed de-
creased GLA activities, which were significantly associated
with increased lyso-Gb3 values (p = 0.0017; r2 = 0.6410;
Fig. 2b). In this analysis a residual GLA activity of <40–
50 % was always associated with increased lyso-Gb3 levels
(Fig. 2b). In contrast, in male p.A143T patients such a cor-
relation was statistically not significant (p = 0.2103), since
most males showed only a slightly decreased GLA activity
with a normal lyso-Gb3 level (Fig. 2c).
In addition, p.A143T patients (females as well as
males) had lower values for IVSd (p < 0.01 and p < 0.05,
respectively; Table 2), resulting in lower frequencies of
LVH. This mild cardiac involvement is also reflected by
the distribution of the New York Heart Association
(NYHA) classes, as half of the male p.A143T patients
were classified in NYHA class 0, whereas ~90 % of the
typical FD patients suffered from a more severe heart
failure (NYHA class II-IV, Table 2). The PR intervals
seen on ECG in p.A143T patients were also in a normal
range (mean: 157 ± 20 ms) and not shortened as typical
for FD [24]. All p.A143T patients had a lower ACR (p <
0.001) compared to other FD missense mutation pa-
tients, resulting in a lower risk for albuminuria (females:
p = 0.0031, males: p < 0.0001; Table 2). The eGFR values
and raw serum creatinine levels were comparable in all
analyzed patients (Table 2). Male patients with missense
mutation were more often treated with RAAS blockers
(Table 2). The mild organ involvement was also demon-
strated by the evaluation of disease scores in that pa-
tients with p.A143T (females as well as males) presented
with lower values of MSSI and DS3 subscores as patients
with other missense mutations (Table 2). In detail,
female p.A143T patients had lower cardiac scores (both,
MSSI and DS3) and males lower renal scores (both,
MSSI and DS3). Furthermore, in contrast to patients
with other missense mutations (MSSI: p = 0.0076), in-
creasing MSSI scores were not associated with increas-
ing age (MSSI: p = 0.4593).
According to the TOAST criteria [17] six additional (2
heterozygous females and 4 hemizygous males) unrelated
p.A143T patients with a mean age of 41.3 ± 5.6 years (age
at event) suffered from stroke (n = 5) or TIA (n = 1) of
either unknown (n = 4), macroangiopathic (n = 1), or other
origin (A. carotis interna dissection, n = 1) before their first
assessment. Of note, similar to the index patient, four pa-
tients with cryptogenic stroke/TIA were the first of their
families presenting at the participating FD centers. Al-
though subsequent family screening revealed more
p.A143T relatives, none of these suffered from stroke/TIA.
Additionally, family members without p.A143T were free
of neurological events.
Figure 1 shows representative magnet resonance images
(MRI) of three p.A143T patients (1 male/ 2 females) suffer-
ing from stroke/TIA. Both females showed random X
chromosome inactivation (allele ratios for index patient
50:50 and TIA patient: 60:40) in blood samples (leukocytes)
(Additional file 2: Figure S1).
Of note, p.A143T patients suffering from stroke/TIA
had slightly decreased residual GLA activities, and/or in-
creased lyso-Gb3 levels.
Discussion
To determine the clinical impact of the GLA p.A143T
variation, we retrospectively analyzed 25 heterozygous
(females) and hemizygous (males) adult Fabry patients
with this variation and compared gender-specific their
clinical symptoms and manifestations with a well-
Table 1 Symptoms and manifestations in p.A143T patients and patients with missense GLA mutations
p.A143T Fabry patients Missense mutation patients
Total (n = 25) Female (n = 15) Male (n = 10) Total (n = 58) Female (n = 39) Male (n = 19)
gastrointestinal pain, n 12 (48.0) 8 (53.3)* 4 (40.0) 11 (20.0) 6 (16.2) 5 (27.8)
diarrhea, n 8 (32.0) 6 (40.0)** 2 (20.0) 5 (9.1) 2 (5.4) 3 (16.7)
tinnitus, n 7 (29.2) 4 (28.6) 3 (30.0) 6 (10.7) 6 (16.2) 0 (0.0)
neuropathic pain, n 7 (28.0) 4 (26.7) 3 (30.0) 26 (45.6) 18 (47.4) 8 (42.1)
hypohidrosis, n 6 (24.0) 4 (26.7) 2 (20.0) 18 (32.1) 11 (29.0) 7 (38.9)
fatigue, n 5 (20.0) 4 (26.7) 1 (10.0) 10 (18.9) 8 (23.5) 2 (10.5)
hypacusis, n 3 (12.5) 1 (7.1) 2 (20.0) 5 (8.8) 5 (13.2) 0 (0.0)
dyspnea, n 3 (12.0) 3 (20.0) 0 (0.0) 12 (21.1) 8 (21.1) 4 (21.1)
edema, n 1 (4.2) 1 (6.7) 0 (0.0) 2 (3.6) 0 (0.0) 2 (10.5)
cornea verticillata, n 0 (0.0) 0 (0.0) 0 (0.0) 9 (19.6) 8 (29.6)* 1 (5.3)
LVEF, % 63.1 ± 6.4 60.9 ± 6.2 66.2 ± 5.6 63.2 ± 9.6 64.5 ± 9.8 60.6 ± 8.8
Values are given as mean ± SD for continuous data or n (%) for categorical data. Continuous values were compared using unpaired Student’s t test and categorical
values have been tested with Fisher’s exact test (both two-sided). LVEF: left ventricular ejection fraction. Patients have been gender-specific compared.
*p < 0.05, **p < 0.01
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Table 2 Clinical data and parameters
p.A143T patients Missense mutation patients
Total (n = 25) Female (n = 15) Male (n = 10) Total (n = 58) Female (n = 39) Male (n = 19)
age, years 46.3 ± 13.7 48.7 ± 14.3 42.7 ± 12.6 44.1 ± 16.6 47.7 ± 17.3 36.8 ± 12.6
body weight, kg 76.6 ± 20.4 65.8 ± 10.7 92.7 ± 21.4 75.8 ± 19.6 71.6 ± 19.1 83.8 ± 18.3
body height, cm 172.0 ± 10.9 166.1 ± 5.1 181.0 ± 11.3 171.9 ± 9.4 167.0 ± 5.9 181.6 ± 7.2
BMI, kg/m2 25.6 ± 4.8 24.0 ± 4.3 28.0 ± 4.5 25.5 ± 5.8 25.6 ± 6.3 25.3 ± 4.8
GLA activity (normal range
100–250 %) , % of reference
65 [25–181] 100 [54–181] 48 [25–72] 80 [0–272] 166 [34–272]* 13 [0–69]**
lyso-Gb3 within reference range
(<0.9 ng/ml), n
19 (82.6) 12 (85.7) 7 (77.8) 9 (22.5) 8 (30.8)** 1 (7.1)***
lyso-Gb3, ng/ml 0.7 ± 0.3 0.6 ± 0.3 0.8 ± 0.3 13.0 ± 16.0 4.5 ± 4.8** 30.2 ± 16.9****
ERT, na 10 (40.0) 4 (26.7) 6 (60.0) 25 (43.1) 12 (30.8) 13 (68.4)
Fabry crisis, n 2 (8.0) 2 (13.3) 0 (0.0) 8 (15.1) 5 (14.7) 3 (15.8)
stroke/TIA, n 7 (28.0) 3 (20.0) 4 (40.0) 5 (8.6) 2 (5.1) 3 (15.8)
IVSd, mm 9.0 ± 1.8 8.3 ± 1.8 9.8 ± 1.4 11.6 ± 5.0 10.6 ± 3.2** 14.0 ± 7.3*
LVH (IVSd > 12 mm), n 3 (12.0) 1 (6.7) 2 (20.0) 19 (40.4) 11 (33.3) 8 (57.1)
pacemaker, n 0 (0.0) 0 (0.0) 0 (0.0) 1 (1.7) 1 (2.6) 0 (0.0)
NYHA class, n
0 8 (33.3) 3 (21.4) 5 (50.0) 9 (15.5) 7 (18.0) 2 (10.5)*
I 15 (62.5) 10 (71.4) 5 (50.0) 36 (62.1) 23 (59.0) 13 (68.4)
II 1 (4.2) 1 (7.1) 0 (0.0) 10 (17.2) 8 (20.5) 2 (10.5)
III 0 (0.0) 0 (0.0) 0 (0.0) 3 (5.2) 1 (2.6) 2 (10.5)
IV 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
ACR, mg albumin/ g creatinine 7 [0–14323] 12 [0–14323] 1 [0–12] 82 [0–4080] 59 [0–4080]*** 195 [0–2668]****
albuminuria (>30 mg/g), n 4 (16.7) 4 (28.6) 0 (0.0) 37 (82.2) 22 (75.9)** 15 (93.8)****
creatinine, mg/dl 0.86 ± 0.31 0.80 ± 0.35 0.96 ± 0.20 0.86 ± 0.38 0.73 ± 0.18 1.12 ± 0.53
eGFR, ml/min/1.73 m2 95.6 ± 17.6 95.0 ± 16.5 96.4 ± 20.1 97.3 ± 27.5 98.3 ± 21.4 95.2 ± 37.6
dialysis, n 0 (0.0) 0 (0.0) 0 (0.0) 1 (1.7) 0 (0.0) 1 (5.3)
NTX, n 0 (0.0) 0 (0.0) 0 (0.0) 1 (1.7) 0 (0.0) 1 (5.3)
CKD stage, n
G1 (≥90 ml/min/1.73 m2) 18 (72.0) 11 (73.3) 7 (70.0) 37 (67.3) 26 (70.3) 11 (61.1)
G2 (60–89 ml/min/1.73 m2) 6 (24.0) 4 (26.7) 2 (20.0) 12 (21.8) 9 (24.3) 3 (16.7)
G3 (30–59 ml/min/1.73 m2) 1 (4.0) 0 (0.0) 1 (10.0) 6 (10.9) 2 (5.4) 4 (22.2)














Table 2 Clinical data and parameters (Continued)
G5 (<15 ml/min/1.73 m2) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
RAAS blockers, n 8 (32.0) 5 (33.3) 3 (30.0) 18 (54.6) 10 (43.5) 8 (80.0)*
diuretics, n 2 (8.0) 0 (0.0) 2 (20.0) 5 (16.1) 5 (23.8) 0 (0.0)
analgesics, n 2 (8.0) 1 (6.7) 1 (10.0) 6 (21.4) 6 (30.0) 0 (0.0)
antidepressants, n 3 (12.0) 2 (13.3) 1 (10.0) 4 (14.8) 4 (21.1) 0 (0.0)
MSSI score (max. 76) 8.5 ± 7.8 8.1 ± 6.7 9.0 ± 9.7 8.9 ± 6.7 8.1 ± 7.5 10.4 ± 4.7
MSSI general (max. 18) 2.4 ± 1.9 2.8 ± 2.3 1.8 ± 1.2 1.8 ± 1.6 1.4 ± 1.6* 2.4 ± 1.3
MSSI cardiac (max. 20) 0.9 ± 2.5 0.6 ± 2.4 1.2 ± 2.6 2.7 ± 4.2 2.9 ± 4.1* 2.3 ± 4.4
MSSI renal (max. 18) 2.1 ± 3.6 2.3 ± 3.8 1.8 ± 3.5 2.4 ± 2.8 1.8 ± 2.8 3.6 ± 2.6*
MSSI neurologic (max. 20) 3.1 ± 4.1 2.4 ± 3.7 4.1 ± 4.6 2.1 ± 2.2 2.1 ± 2.3 2.2 ± 2.2
total DS3 score (max. 80) 6.8 ± 6.5 6.3 ± 6.3 7.6 ± 7.1 9.0 ± 6.2 7.4 ± 6.0 12.1 ± 5.6
total DS3 cardiac (max. 24) 0.6 ± 1.8 0.4 ± 1.3 1.0 ± 2.3 2.8 ± 3.3 2.6 ± 3.2* 3.3 ± 3.5
total DS3 renal (max. 24) 1.3 ± 2.1 1.6 ± 2.3 1.0 ± 1.7 2.4 ± 3.4 1.9 ± 3.0 3.6 ± 3.9*
total DS3 neurologic (max. 16) 4.4 ± 4.7 3.9 ± 4.4 5.2 ± 5.3 3.4 ± 3.5 2.8 ± 3.3 4.8 ± 3.7
Missense mutations were restricted to amino acid substitutions due to single nucleotide mutations within the coding region absent of the catalytic active protein sites. Values are given as mean ± SD, median [range]
for continuous data or n (%) for categorical data. Continuous values were compared using unpaired Student’s t test or Mann Whitney U test if unequal distribution was observed (both two-sided). Categorical values
have been tested with Fisher’s exact test (two-sided). Reference values for plasma lyso-Gb3 < 0.9 ng/ml and GLA activity >32 nmol/h/mg protein in leukocytes. To compare GLA activities between laboratories, values
are presented as the percentage of the laboratory reference value. ACR: albumin-to-creatinine ratio; BMI: body mass index; CKD: chronic kidney disease; DS3: total Disease Severity Scoring System; eGFR: estimated
glomerular filtration rate (calculated via CKD-EPI formula); ERT: enzyme replacement therapy; IVSd: interventricular septum thickness in diastole; LVH: left ventricular hypertrophy; MSSI: Mainz Severity Score Index; NTX:
renal transplantation; NYHA: New York Heart Association; RAAS: renin-angiotensin-aldosterone-system. TIA: transient ischemic attack. aERT initialization within 12 months after 1.st visit. *p < 0.05, **p < 0.01,














characterized group of 58 FD patients (39 heterozygous
females) with other classical missense mutations.
Our main findings are: 1) Most male p.A143T patients
had only slightly decreased residual GLA activities and
normal lyso-Gb3 levels, while GLA activity in heterozy-
gous females was normal; 2) Female and male p.A143T
patients showed a less organ involvement in comparison
to FD patients with other missense mutations; 3) Female
and male p.A143T patients suffering from stroke/TIA
showed no further FD-typical organ manifestations; 4)
No accumulation of neurologic events in family mem-
bers of p.A143T patients with stroke/TIA was observed.
Recent studies suggested the p.A143T variation to
be more likely a neutral variant or a possible modifier
than a disease causing mutation [10, 13]. In our
study, the risk for FD-typical manifestations such as
albuminuria, increased IVSd, and increased disease se-
verity scores was significantly lower in male as well
as female p.A143T patients when compared to groups
with classical FD missense mutations. The higher dis-
ease burden of FD patients with other missense muta-
tions is also demonstrated by severely decreased GLA
activities and/or increased lyso-Gb3 levels, while most
p.A143T patients (females and males) showed normal
values. However, the residual enzymatic activities in
male p.A143T patients revealed a bright variance be-
tween 25 to 72 % of normal GLA activity, which has
also been observed by other investigators especially in
cultured T cells [24]. The only moderately decreased
GLA activity in leukocytes of p.A143T males seems
to be sufficient to keep plasma lyso-Gb3 levels below
the reference value. The ultimate presence or absence
of cellular Gb3 deposits can be diagnosed by appro-
priate tissue biopsies (“gold standard”), which have
not been performed in our study. However, Terryn
and colleagues performed cardiac biopsy in one
female patient with p.A143T with LVH and kidney bi-
opsies in two p.A143T males with renal failure and
microalbuminuria, demonstrating no Gb3 deposits
[13]. Hence, the authors concluded that the presence
of this mutation is not directly associated with FD-
pathology (i.e. Gb3 deposits) and should not be la-
beled as “pathogenic” [13]. The authors also stated
that the lack of Gb3 deposits does not preclude ele-
vated plasma lyso-Gb3 levels that could be pathogenic
and cause endothelial cell dysfunction, and suggested
that this should be analyzed in further studies [13].
Similar to recent studies [9, 10, 13] the risk for pa-
tients with p.A143T in our study with only slightly
reduced GLA activities (males) and/or normal lyso-
Gb3 levels (males and females) for renal and cardiac
end organ damage was reduced in comparison to
other FD patients with classical missense mutations.
In addition, instead of a shortened PR interval on
ECG, which would be typical for a storage disease
[25, 26], the PR interval in our p.A143T patients was
normal, demonstrating also no FD-typical cardiac in-
volvement. The lack of FD-typical manifestations
might be also reflected by the absence of an age ef-
fect on the MSSI score within the p.A143T patients.
Including the index patient, we identified at least 5
neurologic events (stroke or TIA) in heterozygous (fe-
males) as well as hemizygous (males) patients with
p.A143T of unknown etiology, which might be assigned
to FD. This would be in line with recent observations
suggesting that p.A143T may be associated with a
"stroke-only" phenotype [8, 27]. Due to the fact that the
neurologic system seems to be highly sensitive to
Fig. 2 a Distribution of residual GLA activities in patients with p.A143T and Fabry disease patients with other missense GLA mutations. b
Correlation of residual GLA activities with lyso-Gb3 levels in male Fabry disease patients with other missense GLA mutations and c in male patients
with p.A143T. The dotted line represents the upper reference value of measured lyso-Gb3 (0.9 ng/ml). Values are given as medians with 5–95 %
confidence intervals
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reduced GLA activity with neuropathic pain as one of
the first symptoms and early neurologic manifestations
such as stroke and TIA [28, 29], the slightly reduced
GLA activities observed in p.A143T patients might pre-
dominantly manifest in the central nervous system.
However, strokes in FD look like strokes from other
causes and the high frequency of neurological events in
our p.A143T patients (20.0 %) in comparison to mis-
sense mutation patients (8.6 %) seems to be based on a
screening bias. According to the Exome Aggregation
Consortium (ExAC, http://exac.broadinstitute.org/) the
population frequency of c.427G > A is 0.078 % in the
European population, demonstrating a not infrequent
finding of this variation. If the p.A143T variation alone
would be pathogenic, significant more patients with
even this variation with FD-typical signs and symptoms
should have been identified by the participating FD
centers. Our GLA expression analysis revealed no de-
creased mRNA expression compared to healthy con-
trols, suggesting that p.A143T seems to be more likely
a neutral variant. However, it might be possible, that
the variant acts as a modifier of a yet unknown causal
factor.
Conclusions
With respect to our current findings and in accordance
with previous reports, which demonstrate the lack of Gb3
deposits within affected organs [13], we conclude that
p.A143T seems not to be causal for FD but rather a genetic
variant of unknown significance or a genetic modifier. Our
data confirm previous findings that lyso-Gb3 levels seem to
be mostly normal in atypical FD patients [30] or patients
with genetics variants of unknown significance [10].
We suggest that p.A143T patients with stroke/ TIA of
unknown etiology should be further evaluated, since the
diagnosis of FD is not probable and ERT or chaperone
treatment should not be an unreflected option.
Limitations
Possible restrictions of this study are the retrospective
design and the limited number of patients. Due to the
multicenter approach, some parameters (such as lyso-
Gb3 values) and DNA samples for X-chromosome in-
activation analysis were not available for the entire
study cohort. Since DNA for the two analyzed females
was only available from leukocytes, according to Eche-
varria and colleagues a skewed X chromosome inactiva-
tion within other tissues cannot be excluded [31]. The
lack of tissue biopsies demonstrating the ultimately
presence or absence of cellular Gb3 deposits is a limita-
tion. A clear link between genotype and phenotype in
FD is difficult to be established especially in young pa-
tients presented with stroke since it is usually not
possible to document GB3 deposit in the central ner-
vous system.
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